Summary:
- Field Medical, a company based in Cardiff-by-the-Sea, CA, secured $35M in Series B funding for its innovative pulsed field ablation (PFA) technology.
- The funding will support the launch of the VERITAS trial, the development of the FieldForce Ablation System, and the expansion of clinical and regulatory capabilities.
- Field Medical is led by CEO Steven Mickelsen and is focused on advancing PFA technologies for treating complex cardiac arrhythmias.
Article:
Field Medical, a California-based company specializing in cardiac ablation, recently announced a significant milestone by raising $35 million in Series B funding. This funding round, co-led by BioStar Capital and Cue Growth, brings the total amount raised by Field Medical to $75 million. The company plans to utilize these funds to kickstart its pivotal VERITAS trial, enhance the development of the FieldForce Ablation System, and further bolster its clinical and regulatory capabilities.
Led by CEO Steven Mickelsen, Field Medical is at the forefront of advancing pulsed field ablation (PFA) technologies to address complex cardiac arrhythmias. The FieldForce Ablation System, a next-generation PFA system, combines innovative catheter design with proprietary FieldBending energy to enable precise and rapid ablation. This novel approach to ventricular tachycardia (VT) ablation signifies a significant leap forward in the field of cardiac treatment.
In line with its ambitious growth trajectory, Field Medical also announced updates to its Board of Directors. The board now includes prominent figures such as Mark Wisniewski, CFO of Enterra Medical, and Marlou Janssen, a seasoned board member with experience in various healthcare companies. These strategic additions to the board further solidify Field Medical’s position as a key player in the cardiac ablation space.
With a strong focus on innovation and patient care, Field Medical is poised to make a lasting impact in the field of cardiac ablation. The company’s dedication to advancing PFA technologies and its recent funding success highlight its commitment to revolutionizing the treatment of complex cardiac arrhythmias. Stay tuned for more updates on Field Medical’s groundbreaking developments.
